Bioimmunate Technologies

Company Overview

Snapshot

Founded in July 2014 by Sigalit Carmel, MD, PhD, Bioimmunate Technologies operates with 1–10 employees. The company has raised $1.95M across two funding rounds. In September 2019, Bioimmunate Technologies secured a Seed round.

Business overview

Bioimmunate Technologies is a medical device company specializing in precision blood filtering technology for select autoimmune diseases. Its platform technology focuses on treating patients with multiple sclerosis (MS) by developing unique biological filters that recognize, capture, and remove harmful MS-related cells from the blood before they reach the central nervous system. The company aims to provide safer, more cost-effective therapies without side effects, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.

Company Intelligence Q&A

What is Bioimmunate Technologies' primary focus?

Bioimmunate Technologies develops precision blood filtering medical technology for select autoimmune diseases, with an initial focus on treating patients with multiple sclerosis (MS).

Who founded Bioimmunate Technologies?

Bioimmunate Technologies was founded by Sigalit Carmel, MD, PhD in July 2014.

What is the core technology behind Bioimmunate's solution for MS?

Bioimmunate Technologies has developed unique biological filters anchored inside special particles that recognize, capture, and remove MS-related cells from a patient's blood before they reach the central nervous system.

Where is Bioimmunate Technologies' main R&D lab located?

The main R&D lab for Bioimmunate Technologies is located at the BioGiv Center at the Hebrew University in Jerusalem.